康芝藥業(300086.SZ):子公司中山愛護通過高新技術企業重新認定
格隆匯3月9日丨康芝藥業(300086.SZ)公佈,公司全資子公司中山愛護日用品有限公司(簡稱“中山愛護”)於近日收到廣東省科學技術廳、廣東省財政廳、國家税務總局廣東省税務局聯合發佈的《高新技術企業證書》,證書編號為GR202144003193,發證日期為2021年12月20日,證書有效期為3年。
該次認定系中山愛護原高新技術企業證書有效期屆滿後進行的重新認定。根據《中華人民共和國企業所得税法》及國家相關税收政策規定,中山愛護自通過高新技術企業重新認定後連續三年(即2021年度至2023年度)將繼續享受國家關於高新技術企業的相關税收優惠政策,即按15%的税率繳納企業所得税。
該次通過高新技術企業認定不影響中山愛護目前適用的企業所得税税收優惠政策,不會對公司經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.